Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

PROteolysis TArgeting Chimeras (PROTACs) has been exploited to degrade putative protein targets. However, the antitumor performance of PROTACs is impaired by their insufficient tumour distribution. Herein, we present de novo designed polymeric PROTAC (POLY-PROTAC) nanotherapeutics for tumour-specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jing, Hou, Bo, Zhu, Qiwen, Yang, Lei, Jiang, Xingyu, Zou, Zhifeng, Li, Xutong, Xu, Tianfeng, Zheng, Mingyue, Chen, Yi-Hung, Xu, Zhiai, Xu, Huixiong, Yu, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325692/
https://www.ncbi.nlm.nih.gov/pubmed/35882867
http://dx.doi.org/10.1038/s41467-022-32050-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325692/
https://www.ncbi.nlm.nih.gov/pubmed/35882867
http://dx.doi.org/10.1038/s41467-022-32050-4

Ejemplares similares